+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07390383

Phase II Study of LBL-024 Combined With Other Drugs for Treating Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-05-13

110

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an open-label, multicenter phase II clinical trial to evaluate the efficacy and safety of LBL-024 combined with other drugs in patients with locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction, a form of advanced solid tumor. This study aims to assess how well the combination therapy works and its safety profile in treating this serious condition. The study includes a safety run-in period where a small number of participants receive LBL-024 combination therapy for 21 days to assess safety and tolerability. If deemed acceptable, the trial proceeds with a randomized, open, positive control design enrolling up to 110 subjects. Participants will be assigned in a 21 ratio to either the experimental group receiving LBL-024 with Oxaliplatin and capecitabine or the control group receiving Tislelizumab, Oxaliplatin, capecitabine, and LBL-024. Capecitabine is taken orally, while the other drugs are given by intravenous infusion. Participants will undergo regular visits for treatment administration, laboratory tests, and monitoring to evaluate response and safety. Researchers will measure outcomes such as the objective response rate, disease control rate, duration of response, drug concentration levels, and immunogenicity from the time of consent through follow-up after drug withdrawal. The study includes assessments of organ function and survival expectations, with treatment and observation continuing until disease progression or other endpoints. The total participation length varies by individual based on treatment response and follow-up needs.

CONDITIONS

Brief Title

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Research Team

L

Lin Shen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here